Jeffrey M. Weinberg, MD, Associate Chair of the Department of Dermatology at St. Luke’s-Roosevelt Hospital Center reviews the pathogenesis and treatment of human immunodeficiency virus (HIV)–associated psoriasis. Psoriasis is a chronic, immune-mediated skin disease affecting approximately 1% to 3% of the HIV-infected population. Psoriasis presents as the first clinical manifestation of HIV or, less commonly, during the advanced stages of HIV when it has progressed to AIDS.
The original articles were featured in a 2-part series published in Cutis®, which reviewed the pathogenesis of HIV-associated psoriasis as well as the various therapeutic regimens that have effectively treated psoriasis in patients with HIV. These therapies address the profound immune dysregulation that defines psoriasis.
References and Resources:
Patel RV, Weinberg JM. Psoriasis in the patient with human immunodeficiency virus, part 1: review of pathogenesis. Cutis. 2008;82:117-122.
Patel RV, Weinberg JM. Psoriasis in the patient with human immunodeficiency virus, part 2: review of treatment. Cutis. 2008;82:202-210.
Dr. Weinberg has disclosed the following:
Consulting Fees: Amgen, Abbott
